Hepatocellular carcinoma
Conditions
Interventions
experimental group:Hepatic artery perfusion chemotherapy + lenvatinib + immune combination therapy
Sponsors
Zhongshan Hospital Xiamen University
Eligibility
Sex/Gender
All
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: 1. Age greater than 18 years old, gender is not limited; ECOGPS score: 0~2; 2. Clinical diagnosis of hepatocellular carcinoma (based on the Chinese primary liver cancer diagnosis and treatment standard 2022 edition); 3. Liver function grade is Child-Pugh class A or B; 4. Patients with ChinaCiverCancerStaging (CNLC) stage IIb, IIIa and IIIb. 5. Have not received other anti-tumor therapy in the past. 6. No contraindications to HAIC or target-free therapy; 7. Sign the informed consent and be able to comply with the requirements of the program; if the patient is unable to sign the informed consent, his/her legal guardian or agent should sign it.
Exclusion criteria
Exclusion criteria: 1. taking antibiotics, probiotics or microbial agents 1 month before and during the treatment; 2. have undergone surgical procedures related to gastrointestinal tract, liver, gallbladder, etc. in the last 1 month; 3. previous or concomitant other malignant tumors; 4. patients with combined serious diseases of heart, lung, kidney, brain, blood and other important organs; 5. patients with combined serious neurological and psychiatric diseases (e.g. epilepsy, depression, mania, seizures, schizophrenia, etc.); 6. patients with unstably controlled diabetes mellitus, hypertension, thyroid disease, etc.; patients with a history of severe retinopathy or indicated by other evidence of retinopathy; 7. Pregnant or breastfeeding women or patients who plan to become pregnant during the study period and are unwilling to use contraception; 8. Subjects whose current condition, in the opinion of the investigator, makes them unsuitable for participation in this study; 9. patients who are concurrently enrolled in other clinical research trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Intestinal flora; | — |
Secondary
| Measure | Time frame |
|---|---|
| Tissue metabolism;Intratumoral microorganisms; | — |
Countries
China
Contacts
Public ContactYongjie Su
Zhongshan Hospital Xiamen University
Outcome results
None listed